The firm said that the test, a hematology-based cellular biomarker that identifies morphological changes within monocyte white blood cells, could speed diagnosis.
The test is based on RNA sequencing and is used to differentiate between idiopathic pulmonary fibrosis and other lung diseases in order to avoid surgery.
The firm said that the new instrument, which prepares slides for cytology and aliquot samples for molecular testing, offers workflow benefits to clinical labs.
